LARIMAR THERAPEUTICS INC. - COMMON STOCK

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia

23 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

16 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

18 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

30 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

19 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics to Participate in Upcoming Investor Conferences

27 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

07 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia

30 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

20 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

09 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

14 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia

11 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

06 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

16 фев 2024 16:20:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

14 фев 2024 06:15:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Announces Proposed Underwritten Public Offering

13 фев 2024 16:18:34 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia

12 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

14 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

01 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

03 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire